Table 2. Outcome measures at week 6 and week 14 for vedolizumab as induction therapy for Crohn's disease and ulcerative colitis.

Crohn's disease	Week 6¥	Week 14
Outcome	(n =42)	MGH (n=31)	BWH (n=57)	Total population (n=88)
Clinical response ‡ - no (%)	25 (59.5)	16 (51.6)	27 (47.4)	43 (48.9)
Clinical remission - no (%)	15 (35.7)	7 (22.6)	14 (24.6)	21 (23.9)
Corticosteroid free remission – no (%)				16 (18.4)

Ulcerative colitis	Week 6¥	Week 14
Outcome	(n =40)	MGH (n=35)	BWH (n=23)	Total population (n=58)
Clinical response ‡ - no (%)	18 (45.0)	18 (51.4)	13 (56.5)	31 (53.5)
Clinical remission - no (%)	6 (15.0)	11 (31.4)	6 (26.1)	17 (29.3)
Corticosteroid free remission – no (%)				12 (21.1)

^¥Week 6 information available for MGH patients only